SAN FRANCISCO, April 29, 2026 /PRNewswire/ -- INNIX, Dreame Technology's premium home entertainment brand, presented its latest high-end television and home cinema product portfolio at a press conference held at the Palace of Fine Arts, San Francisco on April 28th. Focusing on enhancing the user experience, Dreame TV presented a diverse range of display innovations, including TVs, breakthrough display and audio innovations, highlighting its leading position in the industry. This strategic launch represents a significant milestone in INNIX's North American market expansion and underscores the brand's commitment to advancing home entertainment through differentiated, in-house developed technologies.
Global-first Dynamic Sound Engine: INNIX RGB Mini LED Transforming TV R8000F
The INNIX Aura Mini LED R8000 series, a flagship representation of Dreame's high-quality TV technology, quickly became a highlight of the event. The INNIX Aura Mini LED R8000 series introduces the world's first Dynamic Sound Engine—a proprietary audio architecture that dynamically synchronizes acoustic output with mechanical display transformations. This integration enables real-time adaptation of the soundstage in response to changes in screen form factor and orientation.
R8000F is the world's first TV featuring a motion-adaptive 6.2.2 channel dynamic sound engine. Powered by the flagship Dreamind Master AI processor, it delivers millisecond-level real-time optimization of both sound and image—bringing every moment to a professional cinema-grade standard. On the display side, R8000F adopts next-generation RGB-Mini LED technology with direct red, green, and blue backlighting. By controlling color at the light source, it achieves exceptional color purity and expression—featuring 100% BT.2020 ultra-wide gamut and ΔE < 0.7 ultra-high color accuracy.
S100 — Black Crystal True Color Screen+A Soundbar Within, Achieving the Premium Atmosphere Maestro
As expectations for home entertainment continue to rise, users want to see more authentic detail, hear purer sound, and enjoy a simpler, all-in-one design. The S100 was created to meet these needs.
The S100 features Aura Mini LED backlight with full-array local dimming, delivering precise light control and deep blacks. With QLED+ technology producing over 1.07 billion colors, every detail is sharp and every shade true to life. Powered by the custom Dreamind Pro AI Processor, 2K content is intelligently upscaled close to 4K, with adaptive color and clarity tuning for natural, vivid frames. Furthermore, S100 features a Black Crystal True Color Screen, delivering an ultra-low 1.8% reflection, AG25 anti-glare, a stunning 20,000:1 contrast, hyper-realistic colors, and a consistent 178° wide viewing angle without color shift. This effectively eliminates glare even under bright environmental conditions.
At the same time, the S100 integrates a full soundbar into its body, this innovation delivers 4.1.2ch Master Sound System performance with 11 sound units and 70W peak power—far surpassing typical 40W outputs—creating 270° physical sound coverage. Consumers receive both a flagship TV and premium soundbar in one elegant package.
The S100 is not just a TV. It is an "Atmosphere Maestro" — seamlessly fusing sight and sound to deliver a truly cinematic immersive experience at home.
Available in more than 120 countries via over 6,500 retail outlets and flagship stores, Dreame TV seizes this press conference opportunity to position itself as a technological innovator in the global entertainment sphere. It offers high-quality, intelligent designs that revolutionize daily viewing experiences through cutting-edge proprietary technologies.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Dreame TV Shines at DREAME NEXT with Advanced Display and Audio Technologies
Dreame TV Shines at DREAME NEXT with Advanced Display and Audio Technologies
CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) trastuzumab botidotin (舒泰莱®) in HER2-positive unresectable or metastatic breast cancer (BC) have been published in Journal of Clinical Oncology (JCO, impact factor (IF)=44.7). Professor Xichun Hu and Professor Hongxia Wang of Fudan University Shanghai Cancer Center, and Dr. Junyou Ge, Director of the National Engineering Research Center of Targeted Biologics act as the co-senior authors. Professor Jian Zhang of Fudan University Shanghai Cancer Center, Professor Quchang Ouyang of Hunan Cancer Hospital, Professor Qingyuan Zhang of Harbin Medical University Cancer Hospital, Professor Huihui Li of Cancer Hospital of Shandong First Medical University, and Professor Xu Wang of Tianjin Medical University Cancer Institute and Hospital act as the co-first authors. These findings had previously been selected as a Late-Breaking Abstract (LBA) and presented as an oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.
This randomized, open-label, multicenter phase III study was designed to evaluate the efficacy and safety of trastuzumab botidotin monotherapy versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic BC who had received prior trastuzumab and taxane-containing regimens. A total of 365 patients were randomized 1:1 to receive trastuzumab botidotin or T-DM1. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR), and secondary endpoints included overall survival (OS), objective response rate (ORR), and duration of response (DoR).
As of the data cutoff date of April 26, 2025, with a median follow-up of 14.9 months, efficacy results showed:
- Median PFS was significantly prolonged in the trastuzumab botidotin group compared with the T-DM1 group (11.1 months vs. 4.4 months; hazard ratio (HR) = 0.39) (Figure A), meeting the primary endpoint of the study; consistent PFS benefit was observed across all prespecified subgroups (Figure B).
- Trastuzumab botidotin group demonstrated deeper and more durable tumor responses compared with T-DM1 group, with an ORR of 76.9% vs. 53.0% and a median DoR of 12.2 months vs. 5.7 months (Figure C).
- OS data were not mature in both groups, but an OS benefit trend was observed in trastuzumab botidotin group, demonstrating a 38% reduction in the risk of death (Figure D).
In terms of safety, patients in the trastuzumab botidotin group had a low incidence of interstitial lung disease (ILD), and the incidences of hematologic, hepatic, and gastrointestinal toxicities were notably lower than those in the T-DM1 group, along with lower rates of serious adverse events (SAEs) and treatment discontinuations. The most common treatment-related adverse events (TRAEs) in trastuzumab botidotin group were ocular events, which could be recovered or reversed after management with standardized strategies.
The publication of the phase III results for trastuzumab botidotin in Journal of Clinical Oncology marks a major international academic breakthrough for a domestically developed HER2 ADC backed by high-level clinical evidence. This is the first phase III trial in China for a HER2 ADC compared head-to-head with T-DM1 with positive results. The data showed that trastuzumab botidotin demonstrated improvements in key efficacy endpoints including PFS, ORR, and DoR, along with a favorable safety profile. Based on these positive results, trastuzumab botidotin has been approved by China's National Medical Products Administration (NMPA) for the treatment of second-line or later HER2-positive BC, becoming the first domestically developed HER2 ADC approved for this indication in China and providing a new treatment option for patients with HER2-positive advanced breast cancer.
About Trastuzumab botidotin(舒泰莱®)
Trastuzumab botidotin is a differentiated HER2 ADC to treat advanced HER2+ solid tumors. As an innovative HER2 ADC developed by the Company, it conjugates a novel, monomethyl auristatin F (MMAF) derivative (a highly cytotoxic tubulin inhibitor, Duo-5) via a stable, enzyme-cleavable linker to a HER2 monoclonal antibody with a DAR of 2. Trastuzumab botidotin specifically binds to HER2 on the surface of tumor cells and is internalized by tumor cells, releasing the toxin molecule Duo-5 inside the cell. Duo-5 induces tumor cell cycle arrest in the G2/M phase, leading to tumor cell apoptosis. After targeting HER2, trastuzumab botidotin can also inhibit the HER2 signaling pathway; it has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
Based on the results of a multi-center, randomized, open-label, controlled Phase 3 KL166-III-06 study, trastuzumab botidotin was approved for marketing by the NMPA for adult patients with unresectable or metastatic HER2 positive BC who have received one or more prior anti-HER2 therapy. At a pre-specified interim analysis, trastuzumab botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS as assessed by the BICR compared with T-DM1; the beneficial trend for OS of trastuzumab botidotin was also observed.
Currently, the Company has initiated an open, multi-center Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase inhibitor payload ADC.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 2 projects with 3 indications are in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
